The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies

ConclusionsThis study suggests that the ER S118P variant does not affect risk for breast cancer or hormone therapy resistance. Germline screening and modification of treatments for patients harboring this variant are likely not warranted.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research